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Purpose: Sevelamer hydrochloride (SH) and lantha-
num carbonate (LC) are calcium-free phosphate bind-
ers used in the clinical management of hyperphos-
phatemia in patients with end-stage renal disease
(ESRD). The objective of this analysis was to assess
the cost-effectiveness of LC monotherapy compared
with SH monotherapy in US patients with ESRD in a
clinical practice setting.
Methods: This was a post hoc assessment of
phosphate binder costs among US patients with ESRD
who converted from SH to LC monotherapy in a
previously published, 16-week, Phase IV, real-world
study. Calculations of drug costs used both average
wholesale price (AWP) and wholesale acquisition
cost (WAC).
Findings: There were 953 patients with available
baseline SH dose data; 950 also had a recorded LC
dose 40 mg at baseline, and 691 had dose data
available for both SH at baseline and LC at week 16
(post hoc analysis population). Baseline demographic
characteristics were similar in excluded patients and
the post hoc analysis population. Mean (SD) serum
phosphate levels were 5.91 (1.66) mg/dL at baseline
and 5.93 (1.85) mg/dL after conversion to LC mono-
therapy for 16 weeks. Mean AWP costs were
US$35.72 (16.89) per day at baseline and US$24.69
(8.28) per day at week 16, yielding an overall mean
cost change (deﬁned as LC cost  SH cost) of
US$11.03 (16.37) per day in favor of LC. The overall
mean WAC cost change was US$9.17 (13.64) per
day. Within baseline SH dose subgroups 2400 to 4800,
44800 to 7200, 47200 to 9600, and 49600 mg/d,
the mean AWP cost change ranged from US$2.78
(9.26) per day in favor of SH for the 2400- to 4800-
mg/d subgroup to US$33.15 (12.58) per day in favor
of LC for the49600-mg/d subgroup. Mean WAC cost
changes showed a similar trend, ranging from US$2.331276(7.72) per day to US$27.59 (10.48) per day. Linear
regression analyses revealed that the inﬂection SH
doses corresponding to a mean cost change of zero
were 4905 mg/d (AWP) and 4908 mg/d (WAC). For
the 455 (66%) patients in the post hoc analysis
population who had baseline SH doses at least as high
(Z5600 mg/d) as these point estimates, the mean SH:
LC tablet ratio wasZ3.7, indicating a mean reduction
in the tablet burden after conversion to LC of Z73%.
Implications: This real-world assessment of com-
parative phosphate binder drug costs between SH and
LC among US patients with ESRD indicates that
average cost savings with LC use increased with
increasing SH doses. Conversion to LC from SH
Z5600 mg/d reduced drug costs and tablet burden
while maintaining serum phosphate levels. (Clin Ther.
2014;36:1276–1286) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: cost-minimization, daily dose, end-stage
renal disease, hyperphosphatemia, lanthanum carbo-
nate, phosphate binder, sevelamer hydrochloride.INTRODUCTION
In patients with end-stage renal disease (ESRD),
dysregulation of renal phosphate excretion results in
elevated serum phosphate levels (hyperphosphate-
mia).1,2 Large epidemiologic studies have shown that
hyperphosphatemia is strongly associated with in-
creased morbidity and all-cause and cardiovascular
mortality in patients with ESRD.3–7 The control ofVolume 36 Number 9
M.S. Keith et al.serum phosphate levels has consequently become an
important therapeutic target in the clinical manage-
ment of patients with ESRD.8 Clinical guidelines
published by the Kidney Disease Outcomes Quality
Initiative9 and the Kidney Disease Improving Global
Outcomes group10 indicate that the management of
hyperphosphatemia in patients with ESRD typically
requires oral phosphate binder therapy in conjunction
with dialysis and dietary phosphorus restriction.
The 2012 US Renal Data System Report, which
covers data through 2010, estimated that the total
ESRD expenditure in the United States was US$47.5
billion, of which US$32.9 billion was incurred by
Medicare (6.3% of the total Medicare budget). A total
of 116,946 incident patients received ESRD therapy,
and the prevalent population was 594,374, including
415,013 patients on dialysis.11 To contain expen-
ditures in the face of the increasing prevalence of
ESRD in the United States, the Centers for Medicare
& Medicaid Services instituted the End-Stage Renal
Disease Prospective Payment System (PPS).12 Sche-
duled for full implementation in 2024,13 the ESRD
PPS is a bundled reimbursement scheme that covers
virtually all ESRD treatment costs within a single ﬁxed
payment to dialysis providers.
In light of these changes to the reimbursement
structure in the United States, the comparative cost-
effectiveness of oral phosphate binders will be a key
factor for dialysis providers to consider in the overall
management of ESRD services. Sevelamer hydrochlor-
ide/carbonate and lanthanum carbonate are the most
commonly used calcium-free phosphate binders in the
United States and are therefore expected to be in-
corporated within the ESRD PPS. The 2 forms of
sevelamer are equivalent in terms of both efﬁcacy14–16
and cost.17 Although several studies have compared
the cost-effectiveness of sevelamer hydrochloride18–21
or lanthanum carbonate22 with that of calcium-based
binders, Park et al23 and Vegter et al24 remain the only
published analyses to date of the comparative cost-
effectiveness of lanthanum carbonate and sevelamer
hydrochloride.
In a Phase IV study of the efﬁcacy of lanthanum
carbonate within a clinical practice setting, Vemuri
et al25 reported that conversion to lanthanum carbo-
nate from other phosphate binder medications resul-
ted in the maintenance of baseline serum phosphate
levels and a signiﬁcantly reduced phosphate binder
dose and tablet burden. In the present study, we reportSeptember 2014a post hoc analysis of patient-level data from the study
by Vemuri et al, with the objective of assessing the
cost-effectiveness of lanthanum carbonate monother-
apy compared with sevelamer hydrochloride mono-
therapy in US patients with ESRD. A key additional
objective was to identify the sevelamer hydrochloride
dose inﬂection point at which conversion to lantha-
num carbonate becomes more cost-effective than
increasing the dose of sevelamer hydrochloride in the
clinical management of hyperphosphatemia.
PATIENTS AND METHODS
Primary Study Design
The study design and patient demographic charac-
teristics were described in detail in the article by
Vemuri et al.25 In brief, the primary study was a 16-
week, open-label, Phase IV, multicenter study of adult
US patients (Z18 years of age) with ESRD who were
converted to lanthanum carbonate monotherapy from
other phosphate binder regimens. There was an initial
screening visit and a 1-week observation period
during which patients remained on the previous
phosphate binder therapy with no dose modiﬁcations
permitted. After the observation period, patients
began a 12-week lanthanum carbonate titration pe-
riod (starting dose, 1500 mg/d; planned maximum
dose, 3750 mg/d) without washout with the aim of
achieving serum phosphate levels within the Kidney
Disease Outcomes Quality Initiative target range of
3.5 to 5.5 mg/dL.9 Patients continued lanthanum
carbonate treatment for an additional 4-week main-
tenance period.
The study was conducted within a clinical practice
setting in which lanthanum carbonate prescriptions
were fulﬁlled at local pharmacies by using the Tri-
alCard (TrialCard Inc, Cary, North Carolina) pro-
gram. Serum phosphate levels were measured at
screening, at baseline (the beginning of the titration
period [week 0]), at the end of the titration period
(week 12), and at the end of the 4-week maintenance
period (week 16). The intention-to-treat population
(n ¼ 2520) comprised patients who received at least 1
dose of lanthanum carbonate and underwent at least 1
efﬁcacy evaluation.
The study was conducted in accordance with the
Declaration of Helsinki. The study protocol was
approved by an institutional review board, and all
patients provided written informed consent before
study participation.1277
Clinical TherapeuticsPresent Evaluation: Post Hoc Analyses
The post hoc analysis population comprised the
speciﬁc subset of patients in the intention-to-treat
population who had received baseline sevelamer hy-
drochloride monotherapy before conversion to lan-
thanum carbonate monotherapy and who had
recorded dose data for both baseline sevelamer hydro-
chloride (at week 0) and lanthanum carbonate (at
week 16). Serum phosphate levels were analyzed at
week 0 and at weeks 12 and 16 of lanthanum
carbonate monotherapy. Phosphate binder drug costs
were based on July 2012 average wholesale prices
(AWPs) and wholesale acquisition costs (WACs); all
costs are given in US dollars. AWP and WAC drug
costs were: $8.82/1000 mg and $7.35/1000 mg,
respectively, for lanthanum carbonate and $3.71/800
mg and $3.09/800 mg, respectively, for sevelamer
hydrochloride.17 No other drug or direct medical
costs were included in the present analyses. Cost
changes were deﬁned as the lanthanum carbonate
cost at week 16 minus the sevelamer hydrochloride
cost at baseline; negative cost changes indicate that
cost savings can be realized by conversion to
lanthanum carbonate therapy.
Phosphate binder drug costs and cost changes were
analyzed in the overall analysis population and in
subgroups of the analysis population categorized
according to the following baseline sevelamerTable I. Patient disposition. Values are given as number
Excluded Patients
(n ¼ 262)
Unknown 6 (2.3)
Completed 3 (1.1)
Withdrew from primary study 253 (96.6)
Primary reason for withdrawal
Adverse event 89 (34.0)
Withdrew consent 60 (22.9)
Investigator/sponsor decision 46 (17.6)
Alternative phosphate binder 28 (10.7)
Death 16 (6.1)
Lost to follow-up 14 (5.3)
There were 953 patients with available baseline sevelamer hydr
carbonate dose 40 mg at baseline, and 691 had dose data a
lanthanum carbonate at week 16 (the post hoc analysis popula
1278hydrochloride dose ranges: 2400 to 4800, 44800 to
7200, 47200 to 9600, and 49600 mg/d. To estimate
the sevelamer hydrochloride dose beyond which aver-
age drug cost savings were obtained, a linear regression
analysis of cost change according to baseline sevelamer
hydrochloride dose was performed, with baseline sev-
elamer hydrochloride dose as the sole independent
variable.
RESULTS
Patients
A total of 953 patients converted from sevelamer
hydrochloride monotherapy to lanthanum carbonate
monotherapy and had recorded baseline sevelamer
hydrochloride dose data. A subset of 691 patients
had recorded dose data for both sevelamer hydro-
chloride at baseline and lanthanum carbonate at week
16 and were included in the post hoc analysis pop-
ulation. Exclusion of patients from the post hoc
analysis population was mainly due to discontinuation
from the primary study (Table I). The most commonly
reported reasons for study discontinuation of excluded
patients were adverse events (n ¼ 89 [34.0%]), with-
drawal of consent (n ¼ 60 [22.9%]), investigator/
sponsor decision (n ¼ 46 [17.6%]), and alternative
phosphate binder (n ¼ 28 [10.7%]). Baseline
demographic and clinical characteristics were similar
in the excluded patients and the post hoc analysis(%).
Post Hoc Analysis
Population (n ¼ 691) Total (N ¼ 953)
0 6 (0.6)
651 (94.2) 654 (68.6)
40 (5.8) 293 (30.7)
13 (1.9) 102 (10.7)
9 (1.3) 69 (7.2)
11 (1.6) 57 (6.0)
4 (0.6) 32 (3.4)
1 (0.1) 17 (1.8)
2 (0.3) 16 (1.7)
ochloride dose data; 950 also had a recorded lanthanum
vailable for both sevelamer hydrochloride at baseline and
tion).
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distribution across baseline sevelamer hydrochloride
dose subgroups showed that the 2400- to 4800-mg/d
subgroup was the largest, accounting for 33% of
patients in the post hoc analysis population (Table III).
Clinical Efficacy
In the post hoc analysis population, mean (SD)
serum phosphate levels at baseline with sevelamer
hydrochloride monotherapy were 5.91 (1.66) mg/dL.
After conversion to lanthanum carbonate monother-
apy, mean serum phosphate levels were similar to
those achieved with baseline sevelamer hydrochloride
monotherapy: 5.82 (1.62) mg/dL and 5.93 (1.85) mg/
dL at weeks 12 and 16, respectively. For each base-
line sevelamer hydrochloride dose subgroup, serumTable II. Baseline demographic and clinical characteris
number (%).
Characteristic
Excluded Patients
(n ¼ 262)
Age n ¼ 262
Mean (SD), y 56.1 (14.35)
Sex n ¼ 262
Male 133 (50.8)
Female 129 (49.2)
Race n ¼ 262
White 127 (48.5)
African American 119 (45.4)
Asian/Paciﬁc Islander 7 (2.7)
Native American 1 (0.4)
Other 8 (3.1)
Albumin n ¼ 248
Mean (SD), g/dL 3.87 (0.463)
Serum phosphate n ¼ 252
Mean (SD), mg/dL 5.81 (1.786)
Sevelamer hydrochloride dose n ¼ 262
Mean (SD), mg/d 7490.1 (3710.79)
Diabetes n ¼ 262
No. (%) 116 (44.3)
Time on dialysis n ¼ 260
Mean (SD), y 4.47 (4.264)
There were 953 patients with available baseline sevelamer hydr
carbonate dose 40 mg at baseline, and 691 had dose data a
lanthanum carbonate at week 16 (the post hoc analysis popula
September 2014phosphate levels were also similar at baseline, week
12, and week 16 (Figure 1).Comparative Assessment of Drug Costs
Table III summarizes the results of the analyses of
AWP and WAC daily drug costs and drug cost changes.
In the post hoc analysis population, mean AWP costs
were $35.72 (16.89) per day for sevelamer hydrochloride
at baseline and $24.69 (8.28) per day for lanthanum
carbonate at week 16, providing a mean overall cost
change when converting from sevelamer hydrochloride
to lanthanum carbonate of $11.03 (16.37) per day.
The mean overall WAC cost change was $9.17 (13.64)
per day. These mean cost changes equate to a 31% mean
cost saving in favor of lanthanum carbonate.tics. Unless otherwise indicated, data are given as
Post Hoc Analysis
Population (n ¼ 691) Total (N ¼ 953)
n ¼ 691 N ¼ 953
57.4 (13.96) 56.1 (14.08)
n ¼ 691 N ¼ 953
403 (58.3) 536 (56.2)
288 (41.7) 417 (43.8)
n ¼ 691 N ¼ 953
356 (51.5) 483 (50.7)
283 (41.0) 402 (42.2)
15 (2.2) 22 (2.3)
5 (0.7) 6 (0.6)
32 (4.6) 40 (4.2)
n ¼ 653 n ¼ 901
3.95 (0.425) 3.93 (0.437)
n ¼ 665 n ¼ 917
5.90 (1.657) 5.88 (1.693)
n ¼ 691 N ¼ 953
7702.5 (3641.55) 7644.1 (3659.99)
n ¼ 691 N ¼ 953
334 (48.3) 450 (47.2)
n ¼ 686 n ¼ 946
3.77 (3.231) 3.96 (3.556)
ochloride dose data; 950 also had a recorded lanthanum
vailable for both sevelamer hydrochloride at baseline and
tion).
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Figure 1. Mean serum phosphate levels across baseline sevelamer hydrochloride (SH) dose subgroups. LC ¼
lanthanum carbonate. The numbers of patients in each subgroup with a week 0 dose of SH, a week
16 dose of lanthanum carbonate (LC), and serum phosphate data are shown above the bars. SH
week 0: mean (SD) serum phosphate levels for patients at baseline. LC week 12 or 16: mean (SD)
serum phosphate levels for patients at week 12 or week 16 of LC treatment.
Clinical TherapeuticsAnalysis of mean drug costs according to baseline
sevelamer hydrochloride dose subgroup (Table III)
showed that lanthanum carbonate costs were higher
than those of sevelamer hydrochloride in the lowest
sevelamer hydrochloride dose subgroup (2400–4800
mg/d). However, as the sevelamer hydrochloride dose
increased above 4800 mg/d, lanthanum carbonate
became less costly than sevelamer hydrochloride,
and the magnitude of the cost change in favor of
lanthanum carbonate increased with the baseline
sevelamer hydrochloride dose. Thus, the mean AWP
cost change was $2.78 (9.26) per day in the sevelamer
hydrochloride 2400- to 4800-mg/d subgroup and
$33.15 (12.58) per day in the 49600-mg/d
subgroup. Cost changes for all other subgroups are
shown in Table III. The mean WAC cost changes
showed a similar trend: $2.33 (7.72) per day and
$27.59 (10.48) per day, respectively.
To estimate the baseline sevelamer hydrochloride
dose at which mean cost savings of zero were obtained
when converting from sevelamer hydrochloride (base-
line) to lanthanum carbonate (week 16) treatment,
simple linear regression analyses of cost changes1280according to baseline sevelamer hydrochloride dose
were performed (Figure 2). The point estimates of the
sevelamer hydrochloride doses corresponding to a
zero mean cost change were 4905 mg/d according to
AWP and 4908 mg/d according to WAC. The
distribution of baseline sevelamer hydrochloride
doses, summarized in Table IV, indicate that 455
(66%) patients in the post hoc analysis population
had baseline doses Z5600 mg/d that were greater
than these point estimates and therefore obtained
mean cost savings after conversion to lanthanum
carbonate. Analysis of maximum cost changes
according to observed baseline sevelamer hydrochlo-
ride dose revealed that all patients with sevelamer
hydrochloride doses Z7200 mg/d at baseline (n ¼
425 [62%]) achieved AWP and WAC cost savings
after conversion to lanthanum carbonate.
Comparative Assessment of Tablet Burden
Table V presents the ratio of sevelamer hydro-
chloride 800-mg tablets at baseline to lanthanum
carbonate 1000-mg tablets at week 16 according to
sevelamer hydrochloride dose subgroup. The overallVolume 36 Number 9
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September 2014mean tablet ratio was 3.8 (2.5). In line with the
cost change data presented earlier, the mean
sevelamer hydrochloride:lanthanum carbonate
tablet ratio increased from 2.6 (2.2) in the lowest
sevelamer hydrochloride dose subgroup (2400–
4800 mg/d) to 5.7 (2.6) in the highest dose
subgroup (49600 mg/d). For the 455 patients
with baseline sevelamer hydrochloride doses
Z5600 mg/d who achieved mean cost savings,
the mean sevelamer hydrochloride:lanthanum
carbonate tablet ratio was Z3.7 (mean tablets/
d, 8.8 [0.4] vs 2.8 [0.9], respectively). This ﬁnding
corresponds to a mean reduction in the tablet
burden of Z73% after conversion to lanthanum
carbonate.
DISCUSSION
This was a post hoc assessment of the real-world
cost-effectiveness of lanthanum carbonate mono-
therapy compared with sevelamer hydrochloride
monotherapy in US patients with ESRD. With
regard to clinical efﬁcacy, serum phosphate levels
after conversion to lanthanum carbonate mono-
therapy were similar to those achieved with base-
line sevelamer hydrochloride monotherapy, in
accordance with the results of the primary study
of Vemuri et al.25 In a recent analysis of the data
from Vemuri et al, we reported that sevelamer
hydrochloride and lanthanum carbonate achieved
comparable efﬁcacy with an overall dose-relativity
ratio of 2.8.26 The present economic evaluation
of dose data from the study by Vemuri et al
revealed that the overall mean daily per-patient
drug costs (AWPs) for sevelamer hydrochloride
and lanthanum carbonate were $35.72 and
$24.69, respectively. Thus, a sevelamer hydro-
chloride:lanthanum carbonate dose-relativity ratio
of 2.8 is associated with a 31% lower overall cost
for lanthanum carbonate monotherapy compared
with sevelamer hydrochloride monotherapy.
The analysis of drug costs based on daily doses
indicates that, on average, cost savings were
realized for patients who switched from sevelamer
hydrochlorideZ5600 mg/d, doses that were taken
by 66% of patients in the post hoc analysis
population. In the context of the ongoing changes
to reimbursement for US ESRD services,12,27 these
results have clear implications for dialysis pro-
viders considering the appropriate calcium-based1281
Clinical Therapeuticsphosphate binder to be used for the treatment of
hyperphosphatemia. Our analysis suggests that for
patients who require doses of sevelamer hydrochloride40
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Table IV. Maximum cost changes according to
minimum observed baseline sevelamer
hydrochloride (SH) doses.
Minimum
Observed SH
Dose* No. (%)
Maximum
AWP Cost
Change,
US$/d†
Maximum
WAC Cost
Change,
US$/d†
Post hoc analysis
population‡
691 (100) 26.36 21.97
Subgroup
4800 mg/d 605 (87.6) 10.82 9.02
5600 mg/d§ 455 (65.8) 3.40 2.84
6400 mg/d 451 (65.3) 3.40 2.84
6800 mg/d 426 (61.6) 1.54 1.30
7200 mg/dǁ 425 (61.5) 0.31 0.25
8000 mg/d 280 (40.5) 4.02 3.34
AWP and WAC drug costs were US$8.82/1000 mg and
US$7.35/1000 mg, respectively, for LC; and US$3.71/
800 mg and US$3.09/800 mg, respectively, for SH.17
AWP ¼ average wholesale price; LC ¼ lanthanum
carbonate; WAC ¼ wholesale acquisition cost.
*Observed SH doses between 4800 and 8000 mg/d.
†Cost change ¼ LC cost at week 16 – SH cost at week 0.
‡Patients with a record of both a week 0 dose of SH and
a week 16 dose of LC.
§5600 mg/d is the minimum observed dose at or above
the inﬂection points identiﬁed by using linear
regression (4905 mg/d and 4908 mg/d for AWP and
WAC, respectively).
ǁ7200 mg/d is the minimum observed dose at or above
which all observed cost changes (both AWP and WAC)
are negative, indicating that LC is less costly than SH.
M.S. Keith et al.In addition to cost saving, conversion to lanthanum
carbonate 1000-mg tablets from sevelamer hydro-
chloride 800-mg tablets would reduce the mean tablet
burden by470%. Because tablet burden is negatively
correlated with adherence to phosphate binder ther-
apy,28–30 the reduced tablet burden of lanthanum
carbonate would be expected to have a favorable
impact on patient adherence compared with sevelamer
hydrochloride therapy. Unfortunately, we were not
able to evaluate this hypothesis in the present study
because adherence data were not collected by Vemuri
et al.25
The results presented here are consistent with
previous evaluations of the cost-effectiveness of switch-
ing patients with ESRD from sevelamer monotherapy
to lanthanum carbonate monotherapy by using local
cost and dose inputs from the European Union.31,32
Park et al23 showed that lanthanum carbonate is cost-
effective compared with sevelamer hydrochloride in
patients with ESRD previously treated with calcium-
based binders. In addition, several other economic
evaluations have demonstrated the cost-effectiveness
of lanthanum carbonate as second-line treatment for
hyperphosphatemia from UK, US, Canadian, Japanese,
and Australian payer perspectives.22,24,33–35
The primary limitations of the present evaluation
are those inherent to post hoc analyses of clinical
data.36 A limitation common to health economic
analyses is that although ESRD and hyperphos-
phatemia are chronic conditions, our analyses of the
comparative cost-effectiveness of sevelamer hydro-
chloride and lanthanum carbonate were limited to a
relatively short duration (16 weeks). A further limi-
tation is that this economic analysis was restricted to
phosphate binders, which account for only 30% of
total Medicare Parts B and D costs.11 Finally, it should
also be highlighted that these analyses focused on
sevelamer hydrochloride, the most commonly avail-
able sevelamer formulation at the time the primary
study was conducted (2005).25 A buffered sevelamer
formulation, sevelamer carbonate, is now commonly
used in clinical practice. Sevelamer hydrochloride and
sevelamer carbonate have similar drug costs17 and
have been demonstrated to have equivalent efﬁcacy in
controlling serum phosphate levels.14–16 We would
therefore expect our conclusions to be applicable to
sevelamer carbonate; however, this theory will need to
be conﬁrmed by empiric economic comparisons of
lanthanum carbonate and sevelamer carbonate.September 2014CONCLUSIONS
This economic evaluation is important for decision
making in the provision of dialysis services because it
is the ﬁrst to identify the inﬂection point at which
conversion to lanthanum carbonate becomes more
cost-effective than increasing the dose of sevelamer
hydrochloride in patients with ESRD and hyperphos-
phatemia. Phosphate binder drug cost assessments
based on daily doses revealed that conversion to
lanthanum carbonate was more cost-effective than
sevelamer hydrochloride doses ofZ5600 mg/d, which
were taken by 66% of patients at baseline in this
study. Converting patients with ESRD from sevelamer
hydrochloride monotherapy doses of Z5600 mg/d to
lanthanum carbonate monotherapy offers potential
drug cost savings and a reduction in the daily tablet1283
Table V. Tablet burden and tablet ratio according to baseline sevelamer hydrochloride (SH) dose subgroup.
SH Dose Group Phosphate Binder
Tablet Burden
Mean (SD)
SH:LC Tablet Ratio*
Mean (SD) [Median]
Post hoc analysis population† SH (week 0) 9.6 (4.6) 3.8 (2.5) [3.2]
LC (week 16) 2.8 (0.9)
Subgroup
2400–4800 mg/d SH (week 0) 2.6 (2.2) [2.0]
LC (week 16) 5.1 (1.3)
2.5 (1.0)
44800–7200 mg/d SH (week 0) 8.8 (0.4) 3.7 (2.1) [3.0]
LC (week 16) 2.8 (0.9)
47200–9600 mg/d SH (week 0) 11.6 (0.8) 4.3 (1.8) [3.8]
LC (week 16) 3.0 (0.8)
49600 mg/d SH (week 0) 16.4 (3.0) 5.7 (2.6) [5.0]
LC (week 16) 3.2 (0.8)
LC ¼ lanthanum carbonate.
*The ratio of SH 800-mg tablets to LC 1000-mg tablets.
†Patients with a record of both a week 0 dose of SH and a week 16 dose of LC.
Clinical Therapeuticsburden without compromising the effective manage-
ment of serum phosphate levels.ACKNOWLEDGMENTS
Writing and editorial support was provided by Fer-
nando Gibson, PhD, an employee of PharmaGenesis
London, with funding from Shire Development LLC.
All authors contributed equally to the study design,
the collection, analysis, and interpretation of data, and
the writing of the manuscript.CONFLICTS OF INTEREST
This analysis was funded by Shire Development LLC.
The study sponsor had no direct involvement in the study
design, in the collection, analysis, and interpretation of
data, in the writing of the manuscript, or in the decision
to submit the manuscript for publication. Michael S.
Keith and J. Brian Copley are employees of Shire. Peter
Preston and Rosamund J. Wilson are consultants to Shire.REFERENCES
1. Albaaj F, Hutchison A. Hyperphosphataemia in renal
failure: causes, consequences and current management.
Drugs. 2003;63:577–596.12842. Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyper-
phosphatemia of chronic kidney disease. Kidney Int.
2008;74:148–157.
3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK.
Association of serum phosphorus and calcium x phos-
phate product with mortality risk in chronic hemodialysis
patients: a national study. Am J Kidney Dis. 1998;31:
607–617.
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG,
Chertow GM. Mineral metabolism, mortality, and mor-
bidity in maintenance hemodialysis. J Am Soc Nephrol.
2004;15:2208–2218.
5. Menon V, Greene T, Pereira AA, et al. Relationship of
phosphorus and calcium-phosphorus product with mor-
tality in CKD. Am J Kidney Dis. 2005;46:455–463.
6. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for
dialysis patients with different levels of serum calcium,
phosphorus, and PTH: the Dialysis Outcomes and Practice
Patterns Study (DOPPS). Am J Kidney Dis. 2008;52:519–530.
7. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum
phosphate levels and mortality risk among people with
chronic kidney disease. J Am Soc Nephrol. 2005;16:520–
528.
8. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Battleground:
chronic kidney disorders mineral and bone disease—
calcium obsession, vitamin D, and binder confusion. Clin
J Am Soc Nephrol. 2008;3:168–173.Volume 36 Number 9
M.S. Keith et al.9. National Kidney Foundation. K/
DOQI clinical practice guidelines
for bone metabolism and disease
in chronic kidney disease. Am J
Kidney Dis. 2003;42(4 Suppl 3):
S1–201.
10. Kidney Disease: Improving Global
Outcomes (KDIGO) CKD-MBD
Work Group. KDIGO clinical prac-
tice guideline for the diagnosis,
evaluation, prevention, and treat-
ment of Chronic Kidney Disease-
Mineral and Bone Disorder (CKD-
MBD). Kidney Int Suppl. 2009;113:
S1–130.
11. Collins AJ, Foley RN, Herzog C,
et al. US Renal Data System 2012
annual data report. Am J Kidney
Dis. 2013;61(1 Suppl 1):(A7), e1–
476.
12. Centers for Medicare & Medicaid
Services (CMS). Medicare pro-
gram; end-stage renal disease pro-
spective payment system. Final
rule. Fed Regist. 2010;75:49029–
49214.
13. The Senate and House of Repre-
sentatives of the United States of
America. Protecting Access to Medi-
care Act of 2014. H.R. 4302; Pub.L.
113–193.
14. Fishbane S, Delmez J, Suki WN,
et al. A randomized, parallel, open-
label study to compare once-daily
sevelamer carbonate powder dos-
ing with thrice-daily sevelamer hy-
drochloride tablet dosing in CKD
patients on hemodialysis. Am J
Kidney Dis. 2010;55:307–315.
15. Fan S, Ross C, Mitra S, et al. A
randomized, crossover design study
of sevelamer carbonate powder and
sevelamer hydrochloride tablets in
chronic kidney disease patients on
haemodialysis. Nephrol Dial Trans-
plant. 2009;24:3794–3799.
16. Delmez J, Block G, Robertson J,
et al. A randomized, double-blind,
crossover design study of seve-
lamer hydrochloride and sevelamer
carbonate in patients on hemo-
dialysis. Clin Nephrol. 2007;68:
386–391.September 201417. Truven Health Analytics. Red
Book. New York, NY: Thomson
Reuters; 2013.
18. Taylor MJ, Elgazzar HA, Chaplin S,
Goldsmith D, Molony DA. An eco-
nomic evaluation of sevelamer in
patients new to dialysis. Curr Med
Res Opin. 2008;24:601–608.
19. Huybrechts KF, Caro JJ, Wilson
DA, O'Brien JA. Health and eco-
nomic consequences of sevelamer
use for hyperphosphatemia in
patients on hemodialysis. Value
Health. 2005;8:549–561.
20. Manns B, Klarenbach S, Lee H,
Culleton B, Shrive F, Tonelli M.
Economic evaluation of sevelamer
in patients with end-stage renal
disease. Nephrol Dial Transplant.
2007;22:2867–2878.
21. Huybrechts KF, Caro JJ, O'Brien
JA. Prevention and management of
hyperphosphatemia with seve-
lamer in Canada: health and eco-
nomic consequences. Value Health.
2009;12:16–19.
22. Brennan A, Akehurst R, Davis S,
Sakai H, Abbott V. The cost-
effectiveness of lanthanum carbo-
nate in the treatment of hyper-
phosphatemia in patients with
end-stage renal disease. Value
Health. 2007;10:32–41.
23. Park H, Rascati KL, Keith MS,
et al. Cost-effectiveness of lantha-
num carbonate versus sevelamer
hydrochloride for the treatment
of hyperphosphatemia in patients
with end-stage renal disease: a US
payer perspective. Value Health.
2011;14:1002–1009.
24. Vegter S, Tolley K, Keith MS, Lok
CE, Soroka SD, Morton AR. Cost-
effectiveness of lanthanum carbo-
nate in the treatment of hyper-
phosphatemia in dialysis patients:
a Canadian payer perspective. Clin
Ther. 2012;34:1531–1543.
25. Vemuri N, Michelis MF, Matalon
A. Conversion to lanthanum car-
bonate monotherapy effectively
controls serum phosphorus with
a reduced tablet burden: amulticenter open-label study.
BMC Nephrol. 2011;12:49.
26. Wilson RJ, Keith MS, Preston P,
Copley JB. The real-world dose-rel-
ativity of sevelamer hydrochloride
and lanthanum carbonate mono-
therapy in patients with end-stage
renal disease. Adv Ther. 2013;30:
1100–1110.
27. The Senate and House of Repre-
sentatives of the United States of
America. American Taxpayer Relief
Act of 2012. Pub.L. 112–240, H.R.
8, 126 Stat. 2313.
28. Loghman-Adham M. Medication
noncompliance in patients with
chronic disease: issues in dialysis
and renal transplantation. Am J
Manag Care. 2003;9:155–171.
29. Tomasello S, Dhupar S, Sherman
RA. Phosphate binders, K/DOQI
guidelines, and compliance: the
unfortunate reality. Dial Transplant.
2004;33:236–240.
30. Chiu YW, Teitelbaum I, Misra M,
de Leon EM, Adzize T, Mehrotra
R. Pill burden, adherence, hyper-
phosphatemia, and quality of life
in maintenance dialysis patients.
Clin J Am Soc Nephrol. 2009;4:
1089–1096.
31. Gros B, Galan A, Gonzalez-Parra
E, et al. Cost-effectiveness of lan-
thanum carbonate versus seve-
lamer hydrochloride in the
treatment of hyperphosphataemia
in end-stage renal disease patients
in Spain. Nephrol Dial Transplant.
2013;28(Suppl 1):i460–i471.
32. Wilson RJ, Keith M, Copley JB.
Analysis of the cost-effectiveness
of switching from sevelamer car-
bonate to lanthanum carbonate
monotherapy in the European
Union. Nephrol Dial Transplant.
2013;28(Suppl 1):i460–i471.
33. Goto S, Komaba H, Moriwaki K,
et al. Clinical efﬁcacy and cost-
effectiveness of lanthanum carbo-
nate as second-line therapy in
hemodialysis patients in Japan.
Clin J Am Soc Nephrol. 2011;6:
1375–1384.1285
Clinical Therapeutics34. Vegter S, Tolley K, Keith MS,
Postma MJ. Cost-effectiveness of
lanthanum carbonate in the treat-
ment of hyperphosphatemia in
chronic kidney disease before and
during dialysis. Value Health. 2011;
14:852–858.
35. Wilson RJ, Keith MS, Agnew RA,
Copley JB. Analysis of the cost-
effectiveness of switching from sev-
elamer hydrochloride to lanthanum
carbonate monotherapy: applica-
tions for Australian costs. Nephrol-
ogy (Carlton). 2013;18(Suppl 1).
Abstract 195.
36. Curran-Everett D, Milgrom H.
Post-hoc data analysis: beneﬁts
and limitations. Curr Opin Allergy
Clin Immunol. 2013;13:223–224.1286Address correspondence to: Michael S. Keith, PharmD, PhD, Shire, 725
Chesterbrook Boulevard, Wayne, PA 19087-5637. E-mail: mkeith@shire.
comVolume 36 Number 9
